An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial
一种用于治疗血脂异常的口服、肝脏限制性 LXR 反向激动剂:临床前开发和 I 期试验
期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-025-04169-6
Li, Xiaoxu; Benegiamo, Giorgia; Vijayakumar, Archana; Sroda, Natalie; Kimura, Masaki; Huss, Ryan S; Weng, Steve; Murakami, Eisuke; Kirby, Brian J; von Alvensleben, Giacomo V G; Kremoser, Claus; Gane, Edward J; Takebe, Takanori; Myers, Robert P; Subramanian, G Mani; Auwerx, Johan